Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LSBC -- Large Scale Biology Corp. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (121)	8/26/2003 9:03:21 AM
From: nigel bates	Respond to of 144

LSBC Will Introduce Aprotinin for Research in 2004 Tuesday August 26, 7:10 am ET VACAVILLE, Calif.--(BUSINESS WIRE)--Aug. 26, 2003--Large Scale Biology Corporation (Nasdaq:LSBC - News) is poised to enter the research grade aprotinin market during the second quarter of 2004 as a result of continued progress with the field production and biomanufacturing program initiated at its Owensboro, Kentucky facility in April of this year. "LSBC will introduce a safe recombinant aprotinin product to the research market," said President and CEO Kevin J.Ryan. "We'll begin with research and development applications for biomanufacturing as the first commercial phase of our progressive program." Employing its patented GENEWARE® technology, LSBC has conducted field trials of the recombinant aprotinin successfully since April and is now planning industrial scale production of its active pharmaceutical ingredient (API) for use in research and development. Estimates of the biomanufacturing market for research grade aprotinin, a protease inhibitor, range up to $20 million annually. Given global concerns and supply constraints related to bovine-sourced aprotinin, industry analysts perceive an opportunity for LSBC to exploit its unique ability to provide the market with a safer product. GENEWARE provides a method for producing biopharmaceuticals free of human or animal pathogens by using non-GMO, non-food plants as the production host...